Are Ozempic and Wegovy Covered by Medicare Part D?

If you are exploring your Medicare prescription drug options, you are likely wondering about coverage for GLP-1 medications. The rules surrounding whether Ozempic and Wegovy are covered by Medicare Part D have shifted dramatically in recent years. Because these medications are expensive, understanding exactly how and when your plan will pay for them is critical to managing your healthcare budget.

Historically, Medicare drew a hard line between treating diabetes and treating obesity. However, recent FDA approvals and brand-new programs from the Centers for Medicare & Medicaid Services (CMS) have opened new pathways for coverage in 2026 and 2027. This guide breaks down the current rules, the exact costs you can expect, and how new programs might lower your out-of-pocket spending.

Current Part D Rules for Ozempic and Wegovy

To understand your coverage, you first need to know how Medicare views these two medications. While Ozempic and Wegovy contain the exact same active ingredient (semaglutide), the FDA approved them for different primary uses. Medicare Part D plans base their coverage strictly on these FDA-approved indications.

Ozempic is FDA-approved specifically to treat Type 2 diabetes. Because of this, it is widely covered by Medicare Part D plans. However, by law, Medicare Part D cannot cover Ozempic off-label for weight loss. If your doctor prescribes Ozempic solely to help you lose weight and you do not have a Type 2 diabetes diagnosis, your Part D plan will deny the claim.

Wegovy is FDA-approved for chronic weight management. For decades, federal law strictly prohibited Medicare from covering any drug used solely for weight loss. Because of this ban, Wegovy was entirely excluded from standard Medicare formularies. Fortunately, that absolute ban has ended thanks to two major recent developments: a rule change regarding heart health and a temporary demonstration program for weight management.

The March 2024 Rule Change: Wegovy for Heart Health

The first major shift in Wegovy coverage occurred when the FDA approved the drug for a secondary use: reducing cardiovascular risk. Following this approval, CMS issued guidance in March 2024 allowing Medicare Part D plans to cover Wegovy for a very specific group of enrollees.

Under this rule, your Part D plan can cover Wegovy if you meet two strict criteria:

• You have established cardiovascular disease (such as a prior heart attack or stroke).
• You are clinically obese or overweight.

If you meet these criteria, your doctor can submit a prior authorization to your Part D plan demonstrating your cardiovascular history. If approved, your Wegovy prescription will be covered just like any other Tier 3 or Tier 4 brand-name medication on your plan's formulary. You will be responsible for your plan's standard deductibles and copays.

The New July 2026 Medicare GLP-1 Bridge Program

The most significant news for beneficiaries seeking weight loss medications is the launch of the "Medicare GLP-1 Bridge" program. This is a temporary demonstration program created by CMS that runs from July 1, 2026, to December 31, 2027.

This program bridges the gap for enrollees who need Wegovy (and other GLP-1s like Zepbound KwikPen and Foundayo) specifically for weight management, bypassing the traditional Medicare ban on weight loss drugs. Under this program, eligible patients pay a flat $50 per month copay for their medication.

Eligibility for the GLP-1 Bridge Program

To qualify for the $50 copay under the Bridge program, you must meet strict clinical criteria. You must be 18 or older, be enrolled in a Part D plan, and meet one of the following body mass index (BMI) thresholds:

• A BMI of 35 or higher.
• A BMI of 27 or higher combined with specific weight-related comorbidities, such as prediabetes or hypertension.

Crucial Exclusion: Patients who already have a diagnosis of Type 2 diabetes are explicitly excluded from the GLP-1 Bridge program. CMS expects beneficiaries with Type 2 diabetes to access GLP-1 medications like Ozempic through their standard Part D coverage, rather than using the Bridge program for Wegovy.

How the $50 Bridge Copay Affects Your Out-of-Pocket Maximum

If you qualify for the GLP-1 Bridge program, the $50 monthly copay provides incredible upfront savings. However, you must understand how this program interacts with your standard Medicare Part D limits. Many consumer resources miss this critical financial detail.

Medicare Part D has a yearly cap on what you pay for covered medications. The out-of-pocket maximum is capped at $2,100 in 2026 and increases to $2,400 in 2027. Once you spend this amount on covered drugs, you pay nothing for your covered Part D medications for the rest of the calendar year.

Here is the catch: The $50 monthly copay you pay under the GLP-1 Bridge program does not count toward your Part D deductible, nor does it count toward your out-of-pocket maximum.

If you take other expensive medications alongside Wegovy, you will still have to pay your standard copays for those other drugs until you reach the $2,100 (2026) or $2,400 (2027) limit. You cannot use your $50 Wegovy payments to help you reach that catastrophic coverage cap faster. Understanding the difference between your upfront costs and your yearly limits is vital; you can read more in our guide on deductible vs out-of-pocket max limits.

The 2027 Medicare Drug Price Negotiation List

Another major factor impacting the cost of Ozempic and Wegovy is the federal government's new ability to negotiate drug prices directly with pharmaceutical manufacturers. GLP-1 medications are highly utilized by Medicare enrollees, making them a primary target for cost reduction.

Officially, GLP-1 drugs join the Medicare drug price negotiation program starting January 1, 2027. This means that the prices Medicare Part D plans pay to the manufacturers for these medications will be capped at a newly negotiated maximum fair price.

How Negotiated Prices Lower What Plans Pay

When Medicare negotiates a lower price for a drug like Ozempic, the Part D plan spends less money to acquire it. In theory, this should result in lower copays or coinsurance for you at the pharmacy counter. It also reduces the overall financial burden on the Medicare system.

However, because insurance companies will be absorbing different costs in 2027, they may adjust their plan premiums to compensate. CMS projects the average stand-alone Part D premium to be $36 in 2027. But industry experts at KFF warn that if enrollees do not actively shop and switch to lower-cost plans during Open Enrollment, average premiums could jump by 50% to roughly $51. You can learn more about these shifting costs in our breakdown of why standalone Part D premiums are rising in 2027.

Checking Your 2027 Formulary and Tier Placement

Every Medicare Part D plan has a formulary, which is a list of covered drugs broken down into pricing "tiers." Typically, Tiers 1 and 2 are inexpensive generic drugs, while Tiers 3, 4, and 5 contain more expensive brand-name and specialty medications.

Ozempic (for diabetes) and Wegovy (for cardiovascular risk) usually land on Tier 3 or Tier 4. This means that instead of a low fixed copay, you might be responsible for a percentage of the drug's total cost (coinsurance) until you hit your out-of-pocket maximum.

Before your plan pays anything for these higher-tier drugs, you usually have to meet your annual Part D deductible. The maximum allowable deductible is $615 in 2026 and rises to $700 in 2027. If you are prescribed Ozempic in January, you may have to pay that full $615 or $700 out of pocket at the pharmacy counter before your coverage kicks in. To help manage these large upfront costs, beneficiaries can opt into a smoothing program; learn more about how the Medicare Prescription Payment Plan works.

Prior Authorization Rules for Weight and Diabetes Drugs

Because Ozempic and Wegovy are expensive, Medicare Part D plans almost always require "Prior Authorization" (PA) before they will pay for the prescription. Prior authorization is a process where your doctor must prove to your insurance company that the drug is medically necessary and meets the plan's specific coverage criteria.

If you take Ozempic, your doctor must submit lab results confirming your Type 2 diabetes diagnosis. If you do not have this diagnosis, the PA will be denied. If you are seeking Wegovy for cardiovascular risk, your doctor must submit records showing your history of heart disease.

What to Do If Your Prior Authorization Is Denied

Denials are common, especially when rules are changing rapidly. If your plan denies your prescription, do not panic. You have the right to appeal the decision. First, ask your doctor to review the denial letter to ensure they submitted the correct diagnosis codes. Often, a simple clerical error leads to a denial. If the coding is correct, your doctor can file a formal appeal (a "redetermination") with your Part D plan, providing additional clinical notes to justify the prescription.

The Cost of Waiting: Late Enrollment Penalties

If you are healthy and do not currently take expensive medications, you might be tempted to delay signing up for Medicare Part D. However, if you develop a condition later that requires Ozempic or Wegovy, delaying enrollment can result in permanent financial penalties.

Medicare imposes a late enrollment penalty of 1% of the "national base beneficiary premium" for every full month you go without creditable prescription drug coverage after you become eligible. This penalty is added to your monthly premium for as long as you have Medicare drug coverage.

The math works like this:

• The national base premium is $38.99 in 2026.
• The national base premium rises to $41.33 in 2027.

If you wait 24 months to enroll, your penalty in 2027 would be 24% of $41.33, which adds roughly $9.92 to your premium every single month. Over time, this penalty can easily wipe out any savings you gained by delaying enrollment.

Scenarios: How Different Readers Get Coverage

To make these complex rules clearer, let us look at three common scenarios to see how coverage applies based on the 2026 and 2027 rules.

Scenario A: Treating Type 2 Diabetes

Robert is 68 and was recently diagnosed with Type 2 diabetes. His doctor prescribes Ozempic to help manage his blood sugar. Because Robert has a documented diabetes diagnosis, his standard Part D plan approves the prior authorization. Robert pays his plan's $700 deductible for 2027, and then pays a Tier 3 copay for the rest of the year until he hits his $2,400 out-of-pocket maximum.

Scenario B: Cardiovascular Risk

Susan is 71, has a BMI of 31, and suffered a mild heart attack two years ago. She does not have diabetes. Her doctor prescribes Wegovy to reduce her risk of future cardiovascular events. Under the March 2024 CMS guidance, Susan's Part D plan approves the medication. Like Robert, she pays her standard plan deductibles and copays.

Scenario C: Weight Management Only

David is 66, has a BMI of 36, and has high blood pressure, but no history of heart attacks and no diabetes. His doctor prescribes Wegovy for weight management. His standard Part D plan denies the claim because they do not cover weight loss drugs. However, because it is August 2026, David applies for the Medicare GLP-1 Bridge Program. He is approved and pays a flat $50 per month for his Wegovy.

Common Mistakes When Seeking Coverage for Ozempic and Wegovy

Navigating Medicare drug coverage is tricky, and making a mistake can leave you paying the full retail price for these medications. Here are the most common pitfalls to avoid:

Mistake 1: Assuming Ozempic is covered for weight loss. Many people hear that Ozempic helps with weight loss and assume Medicare will pay for it. Part D plans audit these claims strictly. If your medical records do not show a Type 2 diabetes diagnosis, you will not get coverage for Ozempic.

Mistake 2: Missing the Open Enrollment Period. The Annual Open Enrollment Period runs from October 15 to December 7 every year. This is the only time most people can switch Part D plans. If you discover in January that your current plan dropped Wegovy from its formulary or moved it to a more expensive tier, you are generally stuck with that plan for the rest of the year.

Mistake 3: Misunderstanding the Bridge Program Exclusions. If you have Type 2 diabetes and want to use the GLP-1 Bridge program to get Wegovy for $50, you will be denied. CMS explicitly excludes diabetics from the Bridge program because they already have access to GLP-1s through standard Part D.

Checklist: Steps to Get Your GLP-1 Medication Covered

If you and your doctor decide that Ozempic or Wegovy is right for you, follow this step-by-step checklist to ensure you maximize your Medicare benefits:

• Verify your exact diagnosis: Ask your doctor if your medical chart clearly states Type 2 diabetes, cardiovascular disease, or obesity with comorbidities.
• Check your plan's formulary: Log into your Medicare portal or call your Part D provider to confirm exactly which tier your prescribed drug is on.
• Review the step therapy rules: Ask your plan if they require you to try a less expensive medication (like Metformin) before they will approve a GLP-1.
• Prepare for Prior Authorization: Ensure your doctor submits all required lab results and clinical notes with the initial prescription to prevent delays.
• Apply for the Bridge Program (if eligible): If you need Wegovy purely for weight management and meet the BMI criteria, ask your doctor to help you submit the paperwork for the GLP-1 Bridge program between July 2026 and December 2027.

How to Compare Medicare Part D Rates on Rebel Rates

Because coverage rules, tier placements, and premiums for Ozempic and Wegovy vary wildly from one insurance company to the next, staying with the same Part D plan year after year is a guaranteed way to overpay. As GLP-1 medications enter the Medicare drug price negotiation program in 2027, you can expect premiums and formularies to shift significantly.

You do not have to figure this out alone, and you do not have to deal with pushy sales agents. At Rebel Rates, we provide transparent, independent comparisons of prescription drug plans in your zip code. You can easily see which plans cover your specific medications, what your deductibles will be, and your estimated total out-of-pocket costs for the year. When you are ready to stop guessing and start saving, compare Medicare quotes with us to find the lowest rates for your exact needs.